CHA Biotech NK cell culture, freezing technology covered by prestigious journal


CHA Biotech’s patented technology for growing and freezing natural killer (NK) cells has been featured in the Journal of Experimental and Clinical Cancer Research, an international journal providing a quality forum for all oncology work.

CHA Biotech’s patented technology for the cultivation and cryopreservation of NK cells was highlighted in the Journal of Experimental and Clinical Cancer Research.

Together with a research team led by Professor An Hee-jung from the Pathology Department of Bundang Medical Center at CHA University, the company cultured and cryopreserved NK cells from serum of healthy people and confirmed the anti-cancer effect in a mouse cancer model.

The research team’s genetic analysis showed that the anticancer genes NKp44, CD40L and CCR5 in cultured NK cells increased by approximately 1,100-fold, 12,000-fold and 50-fold, respectively.

When administered to the mouse model, the cultured NK cells reduced their tumor size by over 70% or eliminated them, thus confirming the high anticancer effect of NK cells on cancer cells resistant to oncology therapies.

CHA Biotech produced 99% pure NK cells with its original culture technology and used it in recent research.

Feeder cells which secrete substances necessary for the activity and growth of NK cells are generally used when culturing NK cells. However, the company reduced the time and cost of growing NK cells without using feeder cells and prevented possible contamination between different cells that could follow using feeder cells.

CHA Biotech said its mass culture and cryopreservation technology has proven competitive enough for global commercialization by publishing the study results in a prestigious international academic journal.

“The excellence of our culture and cryopreservation technology, essential for global commercialization, has been proven internationally by publication in the prestigious journal,” said Oh Sang-hoon, CEO of CHA Biotech. “We will focus more on the global advancement of NK cell therapy. “

About Hector Hedgepeth

Check Also

Silence Therapeutics Announces First Quarter 2022 Results

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, …

Leave a Reply

Your email address will not be published.